Preparation method of small nucleic acid medicine for rapidly removing endotoxin
Magnetic Fe3O4 microspheres were prepared by hydrothermal method and silver layer was embedded under the BSA system, covalently bonded to solid-load aptamer to form Fe3O4@Ag-aptamer adsorption carrier. Using strong hydrogen bonds and hydrophobic interactions, small nucleic acid drugs were solved In the problem of slow rate when removing endotoxins, efficient endotoxin adsorption effect is achieved.
Patent Information
- Application Number
- CN202410975682.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-19
- Publication Date
- 2024-11-12
AI Technical Summary
The existing small nucleic acid drug aptamer is slow to remove endotoxins, affecting product safety.
Magnetic Fe3O4 microspheres were prepared by hydrothermal method, and sodium borohydride reduction reaction was carried out under the BSA stable system to embed the silver layer, forming Fe3O4@Ag particles, covalent bonded solid-loaded aptamer, forming Fe3O4@Ag-aptamer as an adsorption carrier , using strong hydrogen bonds and hydrophobic interactions to accelerate the adsorption of endotoxins.
The adsorption rate reached 93.3% within 8 minutes, and the adsorption volume reached 99.5% at 50 minutes, significantly increasing the removal rate of endotoxin.
Smart Images

Figure CN118924781A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of pharmaceutical chemistry, and in particular relates to a method for preparing a small nucleic acid drug for rapidly removing endotoxin. Background Art
[0002] Endotoxin (LPS) is a highly toxic inflammatory irritant that can cause fever, sepsis, septic shock, multiple organ failure and even death. It is a characteristic component of the outermost layer of the cell wall of Gram-negative bacteria, mainly composed of lipid A, specific polysaccharide side chains and core oligosaccharides. It will be released only when the bacteria die and the bacterial body is lysed or the bacterial structure is artificially destroyed. Among them, lipid A is the toxic component and biological active center of endotoxin, which is composed of phosphoric acid, fatty acids and various carbohydrates. Since the human body is extremely sensitive to endotoxins and it is not easily destroyed by heating, chlorination and other methods, severe immune reactions may occur. A small dose of endotoxin can cause a rise in body temperature and produce endotoxin shock, which seriously threatens human health. Therefore, accurate detection and removal of LPS is a necessary guarantee to ensure the safety of sterilized products, especially medical devices, biological products, food and water for injection.
[0003] Small nucleic acid drugs are oligonucleotide molecules that intervene in RNA or protein, with a small molecular weight, generally less than 100 nucleotides; according to the structure and mechanism of action, small nucleic acid drugs can be divided into antisense oligonucleotides (ASO), small interfering RNA (si RNA), micro RNA (mi RNA), small activating RNA (saRNA) and nucleic acid aptamers (aptamers), etc. Among them, aptamers, as an oligonucleotide sequence, have the characteristics of high affinity, strong specificity, good stability, and low immunogenicity. They have broad application prospects in targeted drugs, biosensors, drug separation and clinical diagnosis. However, although aptamers have high affinity and high selectivity, due to their relatively small molecules, the nucleotide molecules will undergo different folding in different buffer systems and detection environments, thereby causing changes in three-dimensional structure and configuration, affecting their recognition performance, resulting in a slow removal rate in the application of endotoxin removal. Summary of the invention
[0004] The purpose of the present invention is to provide a method for preparing a small nucleic acid drug for rapidly removing endotoxins, so as to solve the problem in the background art that the existing small nucleic acid drug aptamer, as an adsorption carrier, has a slow rate of removing endotoxins.
[0005] The purpose of the present invention can be achieved through the following technical solutions:
[0006] A method for preparing a small nucleic acid drug for rapidly removing endotoxins comprises the following steps:
[0007] S1. Disperse FeCl3·6H2O in a mixed solvent, add polyethylene glycol and sodium acetate, stir evenly, transfer to a hydrothermal reactor at 180-220°C to react for 4-5h, cool naturally to room temperature, and magnetically separate and wash to obtain Fe3O4 microspheres;
[0008] S2. The Fe3O4 microspheres were dispersed in a BSA (bovine serum albumin) solution, and then an AgNO3 solution was added. After mixing evenly, a NaOH solution was added to adjust to alkalinity, and the reaction was stirred for 1-3 hours. Then, a NaBH4 solution was added dropwise, and ultrasonic mixing was performed for 10-15 minutes. The Fe3O4@Ag particles were obtained by magnetic separation and washing.
[0009] S3. Disperse the Fe3O4@Ag particles in deionized water, mix well, add aptamer, shake and react for 24 hours, add NaCl solution, continue to shake and react the mixed solution for 24 hours, collect by centrifugation, and wash to obtain Fe3O4@Ag-aptamer.
[0010] Furthermore, the dosage ratio of FeCl3·6H2O, mixed solvent, polyethylene glycol and sodium acetate in S1 is 1 g: 15-18 mL: 0.6-0.9 g: 2.4-2.6 g.
[0011] Furthermore, the mixed solvent in S1 is formed by mixing ethylene glycol and diethylene glycol in a volume ratio of 1:1.
[0012] Furthermore, the mass concentration of the BSA solution is 20%; the concentration of the AgNO3 solution is 0.6 mol / L; the concentration of the NaBH4 solution is 0.01 mol / L; and the concentration of the NaOH solution is 0.01 mol / L.
[0013] Furthermore, the dosage ratio of the Fe3O4 microspheres, BSA solution, AgNO3 solution and NaBH4 solution is 1 g: 15 mL: 1.2 mL: 10 mL.
[0014] Furthermore, the stirring speed is 200-300 rpm.
[0015] Furthermore, the concentration of the aptamer is 100 μmol / L; the concentration of the NaCl solution is 0.2×10 -5 mol / L.
[0016] Furthermore, the dosage ratio of the Fe3O4@Ag, deionized water, aptamer and NaCl solution is 0.02 g: 10 mL: 20 μL: 1 mL.
[0017] Compared with the prior art, the present invention has the following beneficial effects:
[0018] 1. The present invention provides a method for preparing a small nucleic acid drug for rapidly removing endotoxins. The method takes endotoxins as affinity targets, prepares magnetic Fe3O4 by a hydrothermal solvent method, and then embeds the magnetic Fe3O4 particles in a silver layer by a sodium borohydride reduction reaction under a BSA stabilization system. The affinity ligand aptamer is fixed on the surface of the magnetic Fe3O4@Ag particles by covalent bonds. The prepared Fe3O4@Ag-aptamer has an obvious adsorption effect on endotoxins as an adsorption carrier. Within 8 minutes, in a solution containing endotoxins (concentration of 50EU / mL), the adsorption rate reaches 93.3% at 8 minutes, and then the adsorption reaches a dynamic equilibrium, and the adsorption amount reaches 99.5% at 50 minutes.
[0019] 2. In the present invention, the magnetic Fe3O4 microspheres are very easy to be positioned, guided and separated under the action of an external magnetic field. A silver layer synthesized in situ by sodium borohydride is introduced on the surface of the microspheres for surface modification, and then the microspheres are covalently linked to the aptamer. Since the nucleotide sequence of the aptamer contains a large number of bases that have strong hydrogen bonding with the lipid A phosphate groups contained in the endotoxin, the aptamer has strong affinity and specificity in the recognition of endotoxins, thereby selectively adsorbing endotoxins. On the other hand, the silver layer synthesized by in situ reduction on the surface of the magnetic Fe3O4 particles contains BSA, which acts as a stabilizer and linker during the synthesis of the silver layer. At the same time, the large number of hydrophobic amino acid residues of the BSA interact with the non-polar parts contained in the endotoxin molecules to achieve synergistic adsorption with the aptamer, thereby effectively accelerating the adsorption effect. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] The present invention will be further described below in conjunction with the accompanying drawings.
[0021] Figure 1 This is a graph showing the relationship between the amount of endotoxin adsorbed by a small nucleic acid drug for rapidly removing endotoxin prepared in Example 1 of the present invention and time. DETAILED DESCRIPTION
[0022] The following will be combined with the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0023] A method for preparing a small nucleic acid drug for rapidly removing endotoxins comprises the following steps:
[0024] S1. Disperse FeCl3·6H2O in a mixed solvent of ethylene glycol and diethylene glycol in a volume ratio of 1:1, then add polyethylene glycol and sodium acetate, stir evenly at a speed of 200-300 rpm, transfer to a hydrothermal reactor at 180-220°C for reaction for 4-5h, cool naturally to room temperature, and obtain Fe3O4 microspheres by magnetic separation and washing; the dosage ratio of FeCl3·6H2O, mixed solvent, polyethylene glycol and sodium acetate is 1g:15-18mL:0.6-0.9g:2.4-2.6g;
[0025] S2. Disperse Fe3O4 microspheres in a BSA solution with a mass concentration of 20%, add 0.6 mol / L AgNO3 solution, mix well, add 0.01 mol / L NaOH solution to adjust to alkalinity, stir at 200-300 rpm for 1-3h, then add dropwise 0.01 mol / L NaBH4 solution dissolved in an ice-water bath, mix ultrasonically for 10-15min, separate magnetically and wash to obtain Fe3O4@Ag particles; the dosage ratio of Fe3O4 microspheres, BSA solution, AgNO3 solution and NaBH4 solution is 1g:15mL:1.2mL:10mL;
[0026] S3. Disperse Fe3O4@Ag particles in deionized water, mix well, add 100 μmol / L aptamer, shake for 24 h, and then add 0.2×10 -5 mol / L NaCl solution, the mixed solution continued to oscillate for 24 hours, and then centrifuged and washed to obtain the Fe3O4@Ag-aptamer adsorption carrier; the dosage ratio of Fe3O4@Ag particles, deionized water, aptamer and NaCl solution was 0.02g:10mL:20μL:1mL.
[0027] Example 1
[0028] A method for preparing a small nucleic acid drug for rapidly removing endotoxins comprises the following steps:
[0029] S1. Disperse 1 g of FeCl3·6H2O in a mixed solvent of 16 mL of ethylene glycol and diethylene glycol in a volume ratio of 1:1, add 0.8 g of polyethylene glycol and 2.5 g of sodium acetate, stir evenly at a speed of 250 rpm, transfer to a hydrothermal reactor at 200 °C and react for 4.5 h, cool naturally to room temperature, and obtain Fe3O4 microspheres by magnetic separation and washing;
[0030] S2. 1g of Fe3O4 microspheres was dispersed in 15mL of 20% BSA solution, and then 1.2mL of 0.6mol / L AgNO3 solution was added. After mixing evenly, 0.01mol / L NaOH solution was added to adjust to alkalinity, and the mixture was stirred at 250rpm for 2h. Then 10mL of 0.01mol / L NaBH4 solution dissolved in ice water bath was added dropwise, and ultrasonic mixing was performed for 13min. Fe3O4@Ag particles were obtained by magnetic separation and washing.
[0031] S3. Disperse 0.02 g of Fe3O4@Ag particles in 10 mL of deionized water, mix well, add 20 μL of 100 μmol / L aptamer, shake for 24 h, and then add 1 mL of 0.2×10 -5 mol / L NaCl solution, the mixed solution continued to oscillate for 24 hours, and then centrifuged and washed to obtain the Fe3O4@Ag-aptamer adsorption carrier.
[0032] Comparative Example 1
[0033] A method for preparing a small nucleic acid drug for removing endotoxins comprises the following steps:
[0034] S1. Disperse 1 g of FeCl3·6H2O in a mixed solvent of 16 mL of ethylene glycol and diethylene glycol in a volume ratio of 1:1, add 0.8 g of polyethylene glycol and 2.5 g of sodium acetate, stir evenly at a speed of 250 rpm, transfer to a hydrothermal reactor at 200 °C and react for 4.5 h, cool naturally to room temperature, and obtain Fe3O4 microspheres by magnetic separation and washing;
[0035] S2. Disperse 0.02 g of Fe3O4 microspheres in 10 mL of deionized water, mix well, add 20 μL of 100 μmol / L aptamer, shake for 24 h, and then add 1 mL of 0.2×10 -5 mol / L NaCl solution, the mixed solution continued to oscillate for 24 hours, and then centrifuged and washed to obtain the Fe3O4-aptamer adsorption carrier.
[0036] Comparative Example 2
[0037] A method for preparing a small nucleic acid drug for removing endotoxins comprises the following steps:
[0038] S1. Add 1.2 mL of 0.6 mol / L AgNO3 solution to 15 mL of 20% BSA solution, mix well, add 0.01 mol / L NaOH solution to adjust to alkalinity, stir at 250 rpm for 2 h, then add 10 mL of 0.01 mol / L NaBH4 solution dissolved in ice water dropwise, mix by ultrasonic for 13 min, centrifuge and collect to obtain Ag particles;
[0039] S3. Disperse 0.02 g of Ag particles in 10 mL of deionized water, mix well, add 20 μL of 100 μmol / L aptamer, shake for 24 h, and then add 1 mL of 0.2×10 -5 mol / L NaCl solution, the mixed solution was shaken for 24 hours, and then collected by centrifugation and washed to obtain the Ag-aptamer adsorption carrier.
[0040] Comparative Example 3
[0041] Aptamer is used as adsorption carrier.
[0042] Comparative Example 4
[0043] A method for preparing a small nucleic acid drug for removing endotoxins comprises the following steps:
[0044] S1. Ag particles were prepared by trisodium citrate reduction method;
[0045] S3. Disperse 0.02 g of Ag particles in 10 mL of deionized water, mix well, add 20 μL of 100 μmol / L aptamer, shake for 24 h, and then add 1 mL of 0.2×10 -5 mol / L NaCl solution, the mixed solution was shaken for 24 hours, and then collected by centrifugation and washed to obtain the Ag-aptamer adsorption carrier.
[0046] The endotoxin adsorption performance of the small nucleic acid drug adsorption carriers prepared in Example 1 and Comparative Examples 1 to 4 was evaluated:
[0047] Take 20 mg of small nucleic acid drug adsorption carrier and disperse it in 2 mL of 50 EU / mL endotoxin solution. Oscillate and adsorb at room temperature. Detect the endotoxin content in the solution at 0, 2, 4, 6, 8, 10, 15, 20, 30, 40, and 50 min respectively. The adsorption rate is calculated as follows:
[0048]
[0049] In formula 1:
[0050] C0 and C1 are the endotoxin contents in the solution before and after adsorption (EU / mL), respectively.
[0051] Endotoxin concentration detection method:
[0052] Pipette 0.1mL adsorption sample and 0.1mL horseshoe crab reagent and mix gently, place in a 37℃ water bath for 10min. Then add 0.1mL horseshoe crab tripeptide, place in a 37℃ water bath for 6min, take out and add 0.5mL sodium nitrite solution, mix well, add 0.5mL ammonium aminosulfonate and mix well, add 0.5mL naphthylethylenediamine and mix well, read on a photoelectric colorimeter with a wavelength of 545nm, check the endotoxin standard curve to obtain the endotoxin content, unit EU / mL.
[0053] The endotoxin content obtained at different times was plotted to obtain a curve of the relationship between adsorption time and endotoxin content. The adsorption time and adsorption amount of the Fe3O4@Ag-aptamer adsorption carrier prepared in Example 1 were as follows: Figure 1 As shown by Figure 1 It can be seen that within 0-8 minutes, the Fe3O4@Ag-aptamer adsorption carrier has an extremely fast adsorption rate for endotoxin, with the adsorption rate reaching 93.3% at 8 minutes, and then the adsorption reaches a dynamic equilibrium, and the adsorption amount reaches 99.5% at 50 minutes.
[0054] The adsorption amount and final adsorption rate of the small nucleic acid drug adsorption carriers of Example 1 and Comparative Examples 1 to 4 at the same time are shown in Table 1:
[0055] Table 1
[0056]
[0057] It can be seen from Table 1 that, compared with Comparative Example 1 and Comparative Example 3, aptamer alone as an adsorption carrier has a certain adsorption property and can achieve specific binding with endotoxin. When aptamer is loaded on magnetic Fe3O4 particles alone, the magnetic Fe3O4 particles can avoid aptamer agglomeration, thereby improving its dispersibility and having a certain influence on its adsorption capacity. It can be seen from Comparative Example 2 and Comparative Example 4 that when aptamer is loaded on silver nanoparticles prepared by sodium borohydride reduction under the BSA system, its adsorption capacity is significantly increased, indicating that under the BSA system, the hydrophobic amino acid residues interact with the non-polar part contained in the endotoxin molecules to achieve synergistic adsorption with aptamer, while the Ag particles prepared by the trisodium citrate reduction method in Comparative Example 4 are not stabilized on the surface of the magnetic Fe3O4 particles by BSA as a stabilizer, and thus do not show synergistic adsorption capacity. Compared with Comparative Example 2 and Example 1, BSA is introduced into the surface of the magnetic Fe3O4 particles by an in situ synthesized silver layer, and the silver layer is covalently linked to the aptamer to achieve the synergistic adsorption capacity of the adsorption carrier prepared by the present invention.
[0058] It should be noted that, in this article, relational terms such as first and second, etc. are only used to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply any such actual relationship or order between these entities or operations. Moreover, the terms "include", "comprises" or any other variations thereof are intended to cover non-exclusive inclusion, so that a process, method, article or device including a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements inherent to such process, method, article or device.
[0059] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.
Claims
1. A method for preparing a small nucleic acid drug for rapidly removing endotoxins, characterized in that: The steps include: S1. Disperse FeCl3·6H2O in a mixed solvent, add polyethylene glycol and sodium acetate, stir evenly, transfer to a hydrothermal reactor at 180-220°C to react for 4-5h, cool naturally to room temperature, and magnetically separate and wash to obtain Fe3O4 microspheres; S2. Disperse Fe3O4 microspheres in BSA solution, add AgNO3 solution, mix well, add NaOH solution to adjust to alkalinity, stir and react for 1-3h, then add NaBH4 solution dropwise, mix ultrasonically for 10-15min, separate magnetically and wash to obtain Fe3O4@Ag particles; S3. Disperse Fe3O4@Ag particles in deionized water, mix well, add aptamer, shake and react for 24 hours, add NaCl solution, continue to shake and react the mixed solution for 24 hours, collect by centrifugation, and wash to obtain Fe3O4@Ag-aptamer.
2. The method for preparing a small nucleic acid drug for rapidly removing endotoxin according to claim 1, characterized in that: The dosage ratio of FeCl3·6H2O, mixed solvent, polyethylene glycol and sodium acetate in S1 is 1 g: 15-18 mL: 0.6-0.9 g: 2.4-2.6 g.
3. The method for preparing a small nucleic acid drug for rapidly removing endotoxin according to claim 1, characterized in that: The mixed solvent in S1 is prepared by mixing ethylene glycol and diethylene glycol in a volume ratio of 1:
1.
4. The method for preparing a small nucleic acid drug for rapidly removing endotoxin according to claim 1, characterized in that: The mass concentration of the BSA solution is 20%; the concentration of the AgNO3 solution is 0.6 mol / L; the concentration of the NaBH4 solution is 0.01 mol / L; and the concentration of the NaOH solution is 0.01 mol / L.
5. The method for preparing a small nucleic acid drug for rapidly removing endotoxin according to claim 1, characterized in that: The dosage ratio of the Fe3O4 microspheres, BSA solution, AgNO3 solution and NaBH4 solution is 1g:15mL:1.2mL:10mL.
6. The method for preparing a small nucleic acid drug for rapidly removing endotoxin according to claim 1, characterized in that: The concentration of the aptamer is 100 μmol / L; the concentration of the NaCl solution is 0.2×10 -5 mol / L.
7. The method for preparing a small nucleic acid drug for rapidly removing endotoxin according to claim 1, characterized in that: The dosage ratio of the Fe3O4@Ag, deionized water, aptamer and NaCl solution is 0.02 g: 10 mL: 20 μL: 1 mL.
8. The method for preparing a small nucleic acid drug for rapidly removing endotoxin according to claim 1, characterized in that: The stirring speed is 200-300 rpm.
